Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 09, 2018 07:30 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals Reports First Quarter 2018 Financial Results

-- New drug applications for omadacycline accepted for priority review by FDA; PDUFA action date in October 2018 -- -- Company on track for a first quarter 2019 omadacycline U.S. launch -- --...
May 01, 2018 16:01 ET | Source: Paratek Pharmaceuticals

Paratek Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BOSTON, May 01, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon...
April 25, 2018 17:03 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals to Report First Quarter 2018 Financial Results on May 9, 2018

BOSTON, April 25, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based...
April 23, 2018 07:30 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals Presents Data Supporting Potential Approval of Omadacycline for Treatment of Community-Acquired Bacterial Pneumonia Based on the EMA Guidelines at ECCMID

Company on track to file marketing authorization applications in the European Union in the second half of 2018 Data on utility in geographic regions also presented MADRID, Spain, April 23, 2018 ...
April 23, 2018 07:30 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals Presents New Microbiology Efficacy Data of Oral-only Omadacycline Against the Most Common Pathogens Associated with Skin Infections

- First presentation of the OASIS-2 topline results - Sub-analysis examining efficacy of oral-only omadacycline on lesion size also presented at ECCMID 2018 MADRID, Spain, April 23, 2018 (GLOBE...
April 19, 2018 08:45 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc. Prices $140 Million of Convertible Senior Subordinated Notes due 2024

BOSTON, April 19, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based...
April 18, 2018 16:01 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc. Announces Proposed Private Offering of $125 Million of Convertible Senior Subordinated Notes due 2024

BOSTON, April 18, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based...
April 13, 2018 16:40 ET | Source: Paratek Pharmaceuticals

Paratek Appoints Rolf K. Hoffman to Company’s Board of Directors

-- Led U.S. and International Commercial Operations at Amgen Inc.-- BOSTON, April 13, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on...
April 12, 2018 07:30 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals Presenting New Data from Omadacycline Development Program at ECCMID 2018

- First oral presentation of the results of OASIS-2, the Phase 3 omadacycline oral-only study in ABSSSI - Poster presentations include new microbiology analyses from OASIS-2 BOSTON, April 12, 2018 ...
April 04, 2018 16:01 ET | Source: Paratek Pharmaceuticals

Paratek’s New Drug Applications for Oral and Intravenous Omadacycline Accepted for Priority Review by FDA

-- PDUFA Action Date in October 2018 -- BOSTON, April 04, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) announced today that the U.S. Food and Drug Administration (FDA) has...